Champions Oncology (CSBR) Cost of Revenue (2017 - 2026)
Champions Oncology (CSBR) posted quarterly Cost of Revenue of $6.8 million for Q2 2026, down 6.34% year-over-year from $7.3 million in Q2 2025, and down 22.91% quarter-over-quarter from $8.8 million in Q1 2026.
Champions Oncology (CSBR) Cost of Revenue (2017 - 2026) Analysis & Trends
Champions Oncology's Cost of Revenue history runs 10 years deep, the most recent figure standing at $6.8 million for Q2 2026.
- In Q2 2026, Cost of Revenue fell 6.34% year-over-year to $6.8 million; the TTM figure through Apr 2026 stood at $30.9 million (up 8.85% YoY), while the FY2026 annual figure was $30.9 million, up 8.84% from the prior year.
- Cost of Revenue for Q2 2026 stood at $6.8 million, down from $8.8 million in the prior quarter.
- The five-year high for Cost of Revenue was $8.8 million in Q1 2026, with the low at $6.2 million in Q2 2022.
- The 5-year median for Cost of Revenue is $7.3 million (2025), against an average of $7.3 million.
- The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 38.57% in 2022, then slipped 15.7% in 2025.
- Champions Oncology's Cost of Revenue stood at $7.4 million in 2022, then declined by 11.08% to $6.6 million in 2023, then grew by 12.24% to $7.4 million in 2024, then declined by 2.23% to $7.3 million in 2025, then decreased by 6.22% to $6.8 million in 2026.
- Business Quant data shows CSBR's Cost of Revenue at $6.8 million in Q2 2026, $8.8 million in Q1 2026, and $7.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 298.26 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 67.21 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 387.98 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 6.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 6.81 Mn |
| Apr 30, 2026 | 6.81 Mn |
| Jan 31, 2026 | 8.83 Mn |
| Jan 31, 2026 | 8.83 Mn |
| Oct 31, 2025 | 7.26 Mn |
| Oct 31, 2025 | 7.26 Mn |
| Jul 31, 2025 | 8.00 Mn |
| Jul 31, 2025 | 8.00 Mn |
| Apr 30, 2025 | 7.27 Mn |
| Apr 30, 2025 | 7.27 Mn |
| Jan 31, 2025 | 6.62 Mn |
| Jan 31, 2025 | 6.62 Mn |
| Oct 31, 2024 | 7.43 Mn |
| Oct 31, 2024 | 7.43 Mn |
| Jul 31, 2024 | 7.07 Mn |
| Jul 31, 2024 | 7.07 Mn |
| Apr 30, 2024 | 7.25 Mn |
| Apr 30, 2024 | 7.25 Mn |
| Jan 31, 2024 | 7.85 Mn |
| Jan 31, 2024 | 7.85 Mn |